Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study

Allopurinol‐related severe cutaneous adverse reactions (SCARs) are strongly associated with HLA‐B*58:01, the allele frequency (AF) of which is largely different among East Asians. However, evidence of population differences in SCAR development and relevance of genetic and/or other risk factors in the real‐world remain unelucidated. This study aimed to evaluate population differences in allopurinol‐related SCAR incidence related to genetic and/or other risk factors among East Asians in the real‐world. A population‐based cohort study was conducted using claims databases from Taiwan, Korea, and Japan. New users of allopurinol (311,846; 868,221; and 18,052 in Taiwan, Korea, and Japan, respectively) were followed up to 1 year. As control drugs, phenytoin and carbamazepine were used. The crude incidence rate ratios (IRRs) of SCARs for allopurinol against phenytoin or carbamazepine were the highest in Taiwan (IRR, 0.62 and 1.22; 95% confidence interval [CI], 0.54–0.72 and 1.01–1.47, respectively), followed by Korea (IRR, 0.34 and 0.82; 95% CI, 0.29–0.40 and 0.77–0.87), and the lowest in Japan (IRR, 0.04 and 0.16; 95% CI, 0.02–0.08 and 0.09–0.29). This order was accordant with that of AF ratios (AFRs) reported of HLA‐B*58:01 against alleles responsible for phenytoin‐ or carbamazepine‐related SCARs. The IRRs were higher in patients with chronic kidney disease, females, and elderly. This study demonstrated population differences in the risk of allopurinol‐related SCAR development among East Asians based on genetic and other common risk factors. This finding will help to promote appropriate risk management for allopurinol‐related SCARs based on ethnic origins.

[1]  J. Kim,et al.  Searching for the culprit drugs for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis from a Nationwide Claim Database in Korea. , 2020, The journal of allergy and clinical immunology. In practice.

[2]  G. Trifirò,et al.  Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy , 2019, Drug safety.

[3]  Swu-Jane Lin,et al.  Taiwan’s National Health Insurance Research Database: past and future , 2019, Clinical epidemiology.

[4]  Yoshiro Saito,et al.  HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians , 2018, Clinical pharmacology and therapeutics.

[5]  Sudha R. Raman,et al.  Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. , 2018, The lancet. Psychiatry.

[6]  Y. Shimo,et al.  Association of HLA-A*31: 01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population , 2018, JAMA neurology.

[7]  Dipak Kalra,et al.  Real world big data for clinical research and drug development. , 2017, Drug discovery today.

[8]  P. Wolkenstein,et al.  Severe cutaneous adverse reactions to drugs , 2017, The Lancet.

[9]  Ju-Young Kim,et al.  Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea , 2016, PloS one.

[10]  Kenneth K C Man,et al.  Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis , 2016, Expert opinion on drug safety.

[11]  S. Silva,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). , 2016, Revista da Associacao Medica Brasileira.

[12]  M. Takeuchi,et al.  Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians , 2016, British journal of clinical pharmacology.

[13]  Kenneth K C Man,et al.  Brief Report: Databases in the Asia-Pacific Region The Potential for a Distributed Network Approach , 2015, Epidemiology.

[14]  M. Lee,et al.  Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015, BMJ : British Medical Journal.

[15]  H. Asada,et al.  Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis , 2015, The Journal of dermatology.

[16]  Michio Kimura,et al.  Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries , 2015, Drug Safety.

[17]  Yea-Huei Kao Yang,et al.  Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries , 2015, Pharmacoepidemiology and drug safety.

[18]  H. Asada,et al.  Sequelae in 145 patients with drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR) , 2015, The Journal of dermatology.

[19]  C. Ahn,et al.  An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing , 2015, Genetics in Medicine.

[20]  S. Tsai,et al.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.

[21]  T. Ishibashi,et al.  A Comparison of the Pharmacokinetics and Drug Safety Among East Asian Populations , 2014, Therapeutic innovation & regulatory science.

[22]  Rajesh Verma,et al.  Severe cutaneous adverse drug reactions. , 2013, Medical journal, Armed Forces India.

[23]  M. Gonçalo,et al.  HLA‐B*58:01 is a risk factor for allopurinol‐induced DRESS and Stevens–Johnson syndrome/toxic epidermal necrolysis in a Portuguese population , 2013, The British journal of dermatology.

[24]  E. Roughead,et al.  Multi‐country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study , 2013, Pharmacoepidemiology and drug safety.

[25]  R. Day,et al.  Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012 , 2013, Drug Safety.

[26]  N. Pratt,et al.  The Asian Pharmacoepidemiology Network (AsPEN): promoting multi‐national collaboration for pharmacoepidemiologic research in Asia , 2013, Pharmacoepidemiology and drug safety.

[27]  C. Sotozono,et al.  A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2011, The Pharmacogenomics Journal.

[28]  Yoshiro Saito,et al.  Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. , 2012, Drug metabolism and pharmacokinetics.

[29]  N. Chaiyakunapruk,et al.  Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis , 2011, BMC Medical Genetics.

[30]  J. Jung,et al.  Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans , 2011, Pharmacogenetics and genomics.

[31]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[32]  M. Camilleri,et al.  Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. , 2010, Mayo Clinic proceedings.

[33]  M. Mockenhaupt,et al.  Severe Cutaneous Adverse Reactions to Drugs (SCAR): Definitions, Diagnostic Criteria, Genetic Predisposition , 2009 .

[34]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[35]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[36]  S‐M Huang,et al.  Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice , 2008, Clinical pharmacology and therapeutics.

[37]  L. Naldi,et al.  Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. , 2008, Journal of the American Academy of Dermatology.

[38]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[40]  J. Roujeau,et al.  Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. , 2002, Dermatology online journal.

[41]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.